About Rubicon Genomics
Rubicon Genomics is a Healthcare company based in Ann Arbor (United States) founded in 2000, and was acquired by Takara Bio in December 2016. Reagents and kits for pre-analytical amplification technologies are supplied. Rubicon Genomics has raised $13.04 million across 6 funding rounds from investors including Takara Bio, Broadoak Capital Partners and Research Corporation Technologies. The company has 33 employees. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Kits and Reagents. Its legal entity is RUBICON GENOMICS INC. Its competitors include RareCyte, Sequenta and seqWell; 3 of its 3 listed competitors have raised funding.
Company details
Rubicon Genomics was founded in 2000 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where reagents and kits for pre-analytical amplification technologies are developed. Three kits are offered for use with Illumina next-generation sequencing systems, while two kits support microarray and PCR applications. These products facilitate sample preparation in genomic research environments.
- Headquarters Ann Arbor, United States
- Employees 33
- Stage Acquired
- SectorsHealthcare
- Website rubicongenomics.com
- Social LinkedIn Facebook
- Acquired by Takara Bio (Dec 2016)
- Legal Name Rubicon Genomics Inc
- Total Equity Funding$13.04M (USD)
in 6 rounds
- Latest Funding Round$2M (USD), Series B
Jul 2015
- InvestorsTakara Bio
& 2 more
- Employee Count33
- Acquired byTakara Bio
(Dec 2016)
Funding Insights of Rubicon Genomics
Rubicon Genomics has successfully raised a total of $13.04M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $2 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.04M
- Total Rounds 6
- Last Round Series B — $2M
- First Round $1.31M
(Mar 2004)
- Investors Count 2
All 6 funding rounds of Rubicon Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2015 | $2M | Series B | – | – | |
| Nov 2007 | $5.91M | Series B | – | – | – |
| Jun 2005 | $1.11M | Series A | – | – | – |
| Dec 2004 | $212,500 | Series A | – | – | – |
| Jul 2004 | $2.5M | Series A | – | – | – |
| Mar 2004 | $1.31M | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in Rubicon Genomics
Rubicon Genomics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Takara Bio, Broadoak Capital Partners and Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research Corporation Technologies is engaged in licensing biomedical technologies. | rctech.com | Tucson, United States | ||
Investment banking services are offered in the United States. | 2006 | broadoak.com | Bethesda, United States | |
Developer of gene-based therapies as well as contract services for the industrial and agricultural sector | 1925 | takara-bio.com | Frankfurt, Germany |
Investor details for Rubicon Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Rubicon Genomics
4 dated milestones of Rubicon Genomics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Rubicon Genomics is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Series B, of $2.0M.
- Exit Acquired by Takara Bio.
Competitors of Rubicon Genomics
Rubicon Genomics has 3 listed competitors in our database, 3 of them funded. They include RareCyte, Sequenta and seqWell.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| rarecyte.com | 2009 | Seattle, United States | $114.33M | 54 | Developer of technologies for the analysis of rare and single cells in the blood | |
| sequenta.com | 2008 | San Francisco, United States | $43.46M | 58 | Immuno-sequencing products are developed for disease diagnostics and treatment. | |
| seqwell.com | 2014 | Beverly, United States | $24.51M | 30 | NGS-based reagents and kits are supplied for life sciences research. |
Detailed competitors of Rubicon Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rubicon Genomics
Websites that share an audience with Rubicon Genomics (rubicongenomics.com).
Websites whose visitors overlap most with Rubicon Genomics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
covarisinc.com | covarisinc.com | 100% | – | ||
| illumina.com | 99% | 672.7K | #61,793 | View details | |
| fluidigm.com | 83% | 1.1K | #14,860,207 | View details | |
| regeneron.com | 79% | 324.3K | #154,450 | View details | |
| bitesizebio.com | 74% | 153.3K | #313,861 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Rubicon Genomics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Rubicon Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rubicon Genomics
Complete news archive for Rubicon Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rubicon Genomics
Rubicon Genomics was founded in 2000 and raised its 1st funding round 4 years after it was founded.
Rubicon Genomics is headquartered in Ann Arbor, United States. It is registered at Ann Arbor, Michigan, United States.
Rubicon Genomics is a funded company, having raised a total of $13.04M across 6 funding rounds to date. The company's 1st funding round was a Seed of $1.31M, raised on Mar 2004.
Rubicon Genomics has 33 employees.
Rubicon Genomics was founded in 2000 and is based in Ann Arbor, United States. Operations focus on the biotechnology sector, where reagents and kits for pre-analytical amplification technologies are developed. Three kits are offered for use with Illumina next-generation sequencing systems, while two kits support microarray and PCR applications. These products facilitate sample preparation in genomic research environments.
Rubicon Genomics has 3 investors. Key investors include Takara Bio, Broadoak Capital Partners, and Research Corporation Technologies.
Rubicon Genomics operates through Rubicon Genomics Inc.
Yes. Rubicon Genomics was acquired by Takara Bio in December 2016.